MANCHESTER, England — Even when C-reactive protein (CRP) levels are normal, patients with seropositive rheumatoid arthritis (RA) could still be experiencing significant disease that persists over time ...
In a real-world, prospective study, upadacitinib demonstrated great potential for the treatment of rheumatoid arthritis (RA) regardless of a patient’s baseline C-reactive protein (CRP) levels.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results